ArticleJournal of medical biochemistry2026
Serum human trophoblast cell surface antigen and T-box protein 5 levels play a role in predicting adverse pregnancy outcomes in eclampsia.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The levels of human trophoblast surface antigen (Trop-2) and T-box protein 5 (TBX5) in the serum of patients with preeclampsia were detected, and their value in predicting adverse pregnancy outcomes was analysed. Methods: A total of 196 pregnant women with preeclampsia who underwent prenatal examinations and delivered in our hospital from October 2021 to September 2024, as well as 196 healthy pregnant women, were selected as the eclampsia group and the control group, respectively. The 196 pregnant women with preeclampsia were divided into two groups according to their pregnancy outcome: the adverse outcome group and the good outcome group. Using the enzyme-linked immunosorbent assay (ELISA), the levels of serum Trop-2 and TBX5 were measured. Using multivariate logistic regression analysis, the factors impacting the various pregnancy outcomes of preeclamptic pregnant women were examined. Results: Compared with the control group, the serum TBX5 levels in the eclampsia group (2 0.8 6± 6 .4 5 mg/L vs. 15.34± 5.07 mg/L), as well as diastolic blood pressure, FBG, 24-hour urine protein, TG, systolic blood pressure and TC, were significantly greater. The levels of Trop-2 ((5.46± 1 .7 2) mg/L vs. (7 .37 ± 2.08 ) mg/L). The total incidences of preterm infants, fetal distress, placental abruption and adverse pregnancy outcomes in the eclampsia group were significantly greater than those in the control group (P< 0.05). The serum TBX5 level in the adverse outcome group ((23.01± 6.66) mg/L vs. (1 9.53± 6.32) mg/L), as well as diastolic blood pressure, FBG, 24-hour urine protein, TG, systolic blood pressure, and TC, were significantly greater than those in the good outcome group. The levels of Trop-2 ((4.90± 1.61) mg/L vs. (5.81± 1.79) mg/L) and HDL-C decreased significantly (P< 0.05); Trop-2 (OR 95% CI: 0.38 (0.28, 0.53)), TBX5 (OR 95% CI: 3.89 (1.88, 8.04)) and 24-hour urine protein (OR: 3.14 (1.82, 5.42)) were influencing factors for the pregnancy outcome of pregnant women with preeclampsia (P< 0.05); and the AUCs of serum Trop-2, TBX5 and their combination in predicting the pregnancy outcome of pregnant women with preeclampsia were 0.79, 0.76 and 0.90, respectively. The combined prediction of the two had a greater predictive value than did Trop-2 or TBX5 alone (all P<0.05). Conclusions: The serum Trop-2 level of pregnant women with preeclampsia is abnormally low, and the TBX5 level is abnormally high. The combination of the two can be used as a biological indicator for evaluating adverse pregnancy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.